Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate

Why It Matters

The forecast positions rare‑disease treatments as a major growth engine for pharma, while regulatory dynamics will shape investment decisions between small molecules and biologics.

Key Takeaways

• Orphan drug sales forecast $400B+ by 2032.
• Small molecules represent 45% of top‑valued orphan pipeline.
• IRA pill‑penalty favors biologics over small molecules.
• FDA inconsistencies delay rare‑disease approvals.
• Pediatric voucher program extended through September 2029.

Pulse Analysis

The rare‑disease market is on track for a transformative expansion, with total sales expected to surpass $400 billion by 2032. This surge reflects not only an aging global population but also advances in genomics and diagnostic tools that are uncovering previously untreatable conditions. Investors are watching the segment closely, as orphan drugs are projected to comprise over one‑fifth of overall pharmaceutical revenue, outpacing many traditional therapeutic areas and attracting heightened M&A activity.

A notable shift within the orphan space is the comeback of small‑molecule drugs. Evaluate reports that nearly half of the top‑valued pipeline assets are oral or injectable small molecules, driven by improved target validation, AI‑enhanced chemistry, and cost‑effective manufacturing. Compared with monoclonal antibodies and gene‑therapy modalities, small molecules offer greater patient convenience, broader distribution, and lower price points, making them attractive to both payers and providers. Companies such as Revolution Medicine and Priovant are leveraging these advantages to advance high‑impact candidates like daraxonrasib and brepocitinib.

Regulatory and policy factors, however, introduce uncertainty. The Inflation Reduction Act’s pill‑penalty limits price‑negotiation protections for small molecules, potentially skewing R&D incentives toward biologics. Simultaneously, an inconsistent FDA—exemplified by recent reversals on gene‑therapy trial designs—has delayed approvals and forced pipeline adjustments. On the upside, the reinstated rare‑pediatric‑disease priority‑review voucher program, extended to 2029, provides an additional lever for accelerating market entry. Pharma executives must balance these incentives and constraints to capture the projected growth while navigating a complex policy landscape.